Compare · MSFT vs SNCE
MSFT vs SNCE
Side-by-side comparison of Microsoft Corporation (MSFT) and Science 37 Holdings Inc. (SNCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MSFT and SNCE operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- MSFT is the larger of the two at $3.10T, about 3360.3x SNCE ($921.1M).
- MSFT has hit the wire 14 times in the past 4 weeks while SNCE has been quiet.
- MSFT has more recent analyst coverage (25 ratings vs 5 for SNCE).
- Company
- Microsoft Corporation
- Science 37 Holdings Inc.
- Price
- $414.69-3.13%
- $5.75+0.17%
- Market cap
- $3.10T
- $921.1M
- 1M return
- +0.68%
- -
- 1Y return
- -11.84%
- -
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1986
- 2020
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 5
Microsoft Corporation
Microsoft Corporation develops, licenses, and supports software, services, devices, and solutions worldwide. Its Productivity and Business Processes segment offers Office, Exchange, SharePoint, Microsoft Teams, Office 365 Security and Compliance, and Skype for Business, as well as related Client Access Licenses (CAL); Skype, Outlook.com, OneDrive, and LinkedIn; and Dynamics 365, a set of cloud-based and on-premises business solutions for organizations and enterprise divisions. Its Intelligent Cloud segment licenses SQL, Windows Servers, Visual Studio, System Center, and related CALs; GitHub that provides a collaboration platform and code hosting service for developers; and Azure, a cloud platform. It also offers support services and Microsoft consulting services to assist customers in developing, deploying, and managing Microsoft server and desktop solutions; and training and certification on Microsoft products. Its More Personal Computing segment provides Windows original equipment manufacturer (OEM) licensing and other non-volume licensing of the Windows operating system; Windows Commercial, such as volume licensing of the Windows operating system, Windows cloud services, and other Windows commercial offerings; patent licensing; Windows Internet of Things; and MSN advertising. It also offers Surface, PC accessories, PCs, tablets, gaming and entertainment consoles, and other devices; Gaming, including Xbox hardware, and Xbox content and services; video games and third-party video game royalties; and Search, including Bing and Microsoft advertising. It sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online stores, and retail stores. It has collaborations with Dynatrace, Inc., Morgan Stanley, Micro Focus, WPP plc, ACI Worldwide, Inc., and iCIMS, Inc., as well as a strategic relationship with Avaya Holdings Corp. Microsoft Corporation was founded in 1975 and is headquartered in Redmond, Washington.
Latest MSFT
- NHS England accelerates AI adoption with Microsoft 365 Copilot to improve service delivery, reduce costs and create more time for care
- SEC Form 8-K filed by Microsoft Corporation
- ModelFront Announces Outcome-Based Pricing
- Pinecone Nexus Now Integrates with Microsoft OneLake, Bringing AI Agents Directly to Enterprise Data
- CEO Microsoft Commercial Althoff Judson sold $7,145,314 worth of shares (15,500 units at $460.99), decreasing direct ownership by 12% to 110,477 units (SEC Form 4)
- Mayo Clinic and Microsoft collaborate to develop a frontier AI model for healthcare
- Chief Accounting Officer Jolla Alice L. covered exercise/tax liability with 413 shares, decreasing direct ownership by 0.58% to 71,149 units (SEC Form 4)
- EVP, Chief Human Resources Off Coleman Amy covered exercise/tax liability with 434 shares, decreasing direct ownership by 0.94% to 45,481 units (SEC Form 4)
- Citizens initiated coverage on Microsoft with a new price target
- AI's Power Crisis Is Accelerating a Potential $2.5 Trillion Hydrogen Market
Latest SNCE
- Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
- Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
- Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial
- Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation
- Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
- Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
- Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
- Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
- Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance